iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
27 sept. 2022 16h10 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the...
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
21 sept. 2022 08h30 HE
|
iBio, Inc.
– Positions Company for leadership in AI-powered drug discovery – – Expands iBio’s immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss...
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate
16 août 2022 09h00 HE
|
iBio, Inc.
- Manufactured first batch of drug substance under cGMP conditions - - Analysis of challenge study data underway - BRYAN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio”...
iBio to Participate in the H.C. Wainwright Global Investment Conference
18 mai 2022 08h00 HE
|
iBio, Inc.
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
12 mai 2022 16h05 HE
|
iBio, Inc.
BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming®...
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
09 mai 2022 08h00 HE
|
iBio, Inc.
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the...
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
05 mai 2022 16h30 HE
|
iBio, Inc.
BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
02 mai 2022 08h00 HE
|
iBio, Inc.
Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & ExpoBOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- iBio,...
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
11 mars 2022 08h00 HE
|
iBio, Inc.
BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
14 févr. 2022 16h05 HE
|
iBio, Inc.
BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming...